Table A3.
Main results of primary and secondary endpoints in patients with GC-induced diabetes vs. patients with normoglycemia.
| All (n = 1913) | GC-Induced Diabetes (n = 399) | Normoglycemia (n = 1514) | OR (95% CI) | p-Value | Adjusted OR 1 (95% CI) | p-Value | |
|---|---|---|---|---|---|---|---|
| Primary Endpoint | |||||||
| Combined endpoint: Death (30 days), cardiovascular events, and infections | 573 (30%) | 139 (34.8%) | 434 (28.7%) | 1.33 (1.05–1.68) | 0.017 | 1.66 (1.18–2.36) | 0.004 |
| Secondary Endpoints | |||||||
| Death (30-days) | 140 (7.3%) | 35 (8.8%) | 105 (6.9%) | 1.3 (0.87–1.92) | 0.211 | 1.49 (0.83–2.68) | 0.180 |
| Cardiovascular events | 202 (10.6%) | 51 (12.8%) | 151 (10%) | 1.32 (0.94–1.86) | 0.105 | 1.5 (0.93–2.58) | 0.091 |
| Infections | 365 (19%) | 86 (21.6%) | 279 (18.4%) | 1.2 (0.93–1.6) | 0.158 | 1.4 (0.94–2.1) | 0.094 |
Data is shown as n (%) or mean/median (standard deviation or interquartile range) per group. 1 adjusted for age, pre-existing comorbidities by Charlson Comorbidity Index [28], GC dose (mg prednisolone equivalent per kg body weight per GC day), indication for GCs, mean glucose, CV of glucose, percent of glucose values in range, and hypoglycemia < 4.0 mmol/L (<72 mg/dL). GC: glucocorticoid.